- Home
- DCOM vs KNSA Comparison
DCOM vs KNSA Comparison
Compare DCOM & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- KNSA
- Stock Information
- Founded
- DCOM 1864
- KNSA 2015
- Country
- DCOM United States
- KNSA United Kingdom
- Employees
- DCOM N/A
- KNSA N/A
- Industry
- DCOM Major Banks
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- KNSA Health Care
- Exchange
- DCOM Nasdaq
- KNSA Nasdaq
- Market Cap
- DCOM 1.2B
- KNSA 1.5B
- IPO Year
- DCOM 1996
- KNSA 2018
- Fundamental
- Price
- DCOM $25.21
- KNSA $20.21
- Analyst Decision
- DCOM Buy
- KNSA Strong Buy
- Analyst Count
- DCOM 4
- KNSA 6
- Target Price
- DCOM $35.50
- KNSA $37.17
- AVG Volume (30 Days)
- DCOM 385.2K
- KNSA 638.0K
- Earning Date
- DCOM 04-22-2025
- KNSA 04-29-2025
- Dividend Yield
- DCOM 3.96%
- KNSA N/A
- EPS Growth
- DCOM N/A
- KNSA N/A
- EPS
- DCOM 0.55
- KNSA N/A
- Revenue
- DCOM $277,986,000.00
- KNSA $423,239,000.00
- Revenue This Year
- DCOM $53.72
- KNSA $37.21
- Revenue Next Year
- DCOM $15.16
- KNSA $2.58
- P/E Ratio
- DCOM $45.87
- KNSA N/A
- Revenue Growth
- DCOM N/A
- KNSA 56.60
- 52 Week Low
- DCOM $17.49
- KNSA $16.56
- 52 Week High
- DCOM $37.60
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- DCOM 39.45
- KNSA 44.56
- Support Level
- DCOM $23.25
- KNSA $18.26
- Resistance Level
- DCOM $25.66
- KNSA $21.24
- Average True Range (ATR)
- DCOM 1.32
- KNSA 1.12
- MACD
- DCOM 0.01
- KNSA -0.12
- Stochastic Oscillator
- DCOM 36.23
- KNSA 44.43
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.